|Articles|April 1, 2004
Imiquimod approved for AKs
Washington - The U.S. Food and Drug Administration (FDA) has granted marketing approval for Aldara (imiquimod) Cream 5 percent for the treatment of actinic keratoses (AK) on the face or scalp in immunocompetent adults. It is the first immune response modifier (IRM) approved for AK.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
The “6-7” Advances for Dermatologists to Look Forward to in 2026
2
Soquelitinib Phase 1 Data Show Sustained Clinical Improvement With Extended Treatment in AD
3
Exploring Type 2 Inflammation and Psoriasis Management at Horizons in Advanced Practice
4
Clinicians See Intersection of Weight Loss and Facial Aging
5














